Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided shortening of bendamustine duration with obinutuzumab in untreated follicular lymphoma
MOH_2021-04-06_009843Phase 2Recruiting
- Sponsor
- ד"ר אורי עבדי, מרכז רפואי מאיר
- Start
- Jan 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab and bendamustine in follicular lymphoma (FL), sponsored by ד"ר אורי עבדי, מרכז רפואי מאיר. Primary endpoint: Efficacy of abbreviated bendamustine duration. Started Jan 2020; status: recruiting.
02
Drugs
obinutuzumabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2021-04-06_009843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-06_009843.